A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

PHASE1CompletedINTERVENTIONAL

Enrollment

176

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Healthy Volunteer

Interventions

DRUG

Lebrikizumab

Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.

Trial Locations (4)

Daytona Beach

Evansville

Madison

Dallas